Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy
Cheri Adams(Gates (United States)), Rebecca Gardner(Seattle Children's Hospital), Ann M. Davis(Seattle Children's Hospital), Michael D. Keller(Children's National), Julie R. Park(Seattle Children's Hospital), Jennifer Michlitsch(UCSF Benioff Children's Hospital), Karin Chen(University of Utah), Paibel Aguayo‐Hiraldo(Children's Hospital of Los Angeles), Mohammad Zahid Hossain(Seattle Children's Hospital), Michael R. Verneris(NHS Blood and Transplant)
Cited by 1
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577